The Food and Drug Administration (FDA) approved the use of magic mushroom's "psychedelic ingredient" to treat depression. The federal agency allowed the life science firm Compass Pathways to conduct a drug trial on August 23 to see its effects on patients who were not cured by traditional medicines for the depressive disorder.
According to Talon Marks, there will be 216 patients that will participate in the said trial in Europe and North America that will start this September. The clinical study will need to begin with a small number of cases as it also tries to lessen the treatment period to one hour and a half.
Compass Pathways will "microdose" the patient with magic mushroom's psychoactive ingredient called psilocybin. Microdose is to give the lowest dose of the said element of the fungus to see its minor effect.
The clinical trial will be under the supervision of psychologists and scientists to assist the participants with their "new feelings and thoughts" while under the examination. As most physicians today give treatments that don't usually work on every patient, the use of magic mushroom may finally give them the cure they have been long waiting.
